QuidelOrtho (QDEL) Q1 2026 earnings review
Core Growth Engine Stalls as Respiratory Weakness Drags Down Earnings
QuidelOrtho's first quarter revealed a reversing trend across major financial metrics. Total revenue fell 11% YoY, driven by a 34% collapse in Point of Care (POC) testing due to a weak respiratory season. Most concerningly, the Labs segment—which management previously touted as a durable core growth driver—shrank 5% YoY amid headwinds in China, the Middle East, and the termination of the Grifols arrangement. Profitability suffered severely: Adjusted EBITDA margin compressed to 17.5% from 23.1% a year ago, and Adjusted EPS swung to a $0.04 loss. Consequently, management slashed its recently issued FY26 guidance across all key metrics.
🐂 Bull Case
The Immunohematology business grew 8% YoY as reported (3% constant currency), driven by consistent demand across North America, China, and JPAC, proving the segment's durable recurring revenue profile.
The completed acquisition of LEX Diagnostics provides a much-needed catalyst for the molecular POC portfolio, adding ultra-fast testing capabilities that could help stabilize the struggling respiratory segment in future seasons.
🐻 Bear Case
The Labs division, constituting over half of total revenue, declined 5% YoY. Management blamed China NHSA pricing guidelines and the Grifols termination, contradicting their narrative of 'underlying business strength'.
Slashing the FY26 guidance just three months after issuing it signals poor visibility. A cut to the free cash flow target to $100-$120M raises alarms regarding the company's deleveraging trajectory.
⚖️ Verdict: 🔴
Bearish. The abrupt reversal in the Labs segment and the severe contraction in margins indicate that the company is struggling to outrun its macroeconomic and respiratory-related headwinds. The swift guidance cut damages management credibility.
Key Themes
Labs Segment Succumbs to Macro Headwinds
A critical red flag emerged in the Labs segment, which reversed from a consistent growth driver in FY25 to a 5% YoY decline in 26Q1 ($353M). Management specifically cited slower distributor sales in China due to impending National Health Security Administration (NHSA) IVD pricing guidelines, business disruptions in the Middle East, and the termination of the Grifols joint business arrangement. This contradicts the positive narrative from late FY25 that the core business was durable and immune to regional volatility.
Severe Margin Compression and Negative Earnings
Profitability is decelerating rapidly. The Adjusted EBITDA margin plummeted 560 basis points YoY to 17.5%. Adjusted diluted EPS fell from $0.74 in 25Q1 to a net loss of $0.04 in 26Q1. The drop in high-margin POC respiratory sales clearly outpaced the company's aggressive cost-saving initiatives executed throughout FY25.
Respiratory Demand Collapse
The POC segment is reversing sharply, down 34% YoY to $113M. Management attributed this to a 'significantly weaker respiratory season.' With respiratory testing becoming increasingly volatile, the baseline revenue for this segment remains highly unpredictable.
Immunohematology Outperformance
Immunohematology was the lone accelerating segment, reporting 8% YoY growth to $138M. Growth was robust across key geographies including North America, China, and the JPAC region, providing crucial stability amidst broader portfolio weakness.
LEX Diagnostics Integration
Following the discontinuation of the Savanna platform in 2025, QuidelOrtho officially completed its acquisition of LEX Diagnostics in April 2026. This ultra-fast molecular diagnostics platform is management's primary long-term bet to capture market share in POC testing and transition the portfolio away from legacy respiratory reliance.
Global Product Rollouts
Management continues to execute on its non-respiratory pipeline, noting the successful U.S. launch of the High-Sensitivity Troponin assay and the ongoing rollout of the VITROS 450 platform in select international markets to better compete for international tenders.
Other KPIs
Reversing. Operating cash flow swung to a $33.0 million usage of cash, compared to a positive $65.6 million generated in the prior year period. This dramatic contraction poses a direct threat to the company's deleveraging targets.
Decelerating. Down 32% from $159.8 million in 25Q1. Cost reductions achieved in 2025 were insufficient to offset the gross margin pressure from lower volume and poor product mix.
Guidance
Decelerating. Cut from the previous $2.70 - $2.90 billion range issued in February. The midpoint of $2.725B implies effectively flat revenue compared to FY25 actuals (~$2.73B), reflecting the integration of China NHSA pricing headwinds and a weaker respiratory baseline.
Decelerating. The previous target was $630 - $670 million. The margin profile was also lowered from 23.3% to 23.0%, indicating that the company is struggling to preserve its margin expansion thesis amid volume pressures.
Decelerating. Lowered significantly from the previous $2.00 - $2.42 range. The new midpoint ($1.90) implies a YoY decline from FY25's $2.12, snapping the narrative of steady bottom-line growth.
Decelerating. Slashed from $120 - $160 million. This reduction severely limits the company's excess cash available for debt paydown, keeping leverage elevated for longer than anticipated.
Key Questions
China NHSA Pricing Impact
How much of the lowered FY26 guidance is strictly attributable to the finalized China NHSA IVD pricing guidelines, and what is the expected structural margin impact on the Labs business in the region?
Grifols Partnership Termination
Can you quantify the exact revenue and margin gap created by the termination of the Grifols joint business arrangement, and what is the timeline to organically replace this lost volume?
LEX Diagnostics Commercialization
With the LEX acquisition now closed, what is the realistic timeline for material revenue contribution, and how much incremental R&D or commercial investment is required in H2 2026 to support its launch?
Cash Flow and Leverage
Given the Q1 operating cash burn and the lowered FCF guidance, is the year-end net leverage target of ~3.8x still attainable, or should investors expect debt reduction to be pushed into 2027?